Videos

Neurology News Network for the week ending November 19, 2022. [WATCH TIME: 3 minutes]

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]

Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.

An overview of dual orexin receptor agonists (DORAs) therapy for the treatment of insomnia in female patients.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]

Advanced practice practitioners share tools they use in their clinics to diagnose sleep disorders.

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Debra Davis, CRN, discuss the relationship between sleep disorders and other health conditions, such as cardiovascular, respiratory, and psychiatric diseases.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]

The division chief of stroke and vascular neurology at Duke Health discussed advantages and capabilities, as well as limitations and barriers of transcranial direct current stimulation to treat poststroke symptoms. [WATCH TIME: 4 minutes]

The executive vice principal of advocacy and healthcare access at the National MS Society spoke on how the Inflation Reduction Act of 2022 will impact patients with MS and what the clinical community should be aware of. [WATCH TIME: 5 minutes]

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]

The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]

An expert in sleep medicine provides insight on the use of traditional insomnia medications in patients as well as DORAs, and common challenges experienced with these treatment options.

Dr Paul Doghramji shares tips for communication with patients once an insomnia diagnosis has been made.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]

The founder and executive director of the Sumaira Foundation discussed her experience living with NMOSD and the global organization she created to help patients with the same condition. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending November 12, 2022. [WATCH TIME: 4 minutes]

The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about her presentation at ECTRIMS 2022 on the treatment of pediatric MS. [WATCH TIME: 5 minutes]

Charlene Gamadelo, MD, describes the different categories of FDA approved treatments for insomnia along with challenges associated with these treatments.

Charlene Gamadelo, MD, provides an overview of commonly utilized insomnia treatment modalities in the treatment of female patients with insomnia.

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]

Advanced practice practitioners discuss different types of sleep disorders in the general population and their impact on quality of life.

Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, and Debra Davis, CRN, provide an overview of the prevalence of insomnia in clinical practice.

Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]

The senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]

The codirector of the ALS Center at Washington University School of Medicine in St. Louis discussed the long-term data of VALOR and its open-label extension assessing tofersen (Biogen) in SOD1 ALS. [WATCH TIME: 4 minutes]

The executive vice principal of advocacy and healthcare access at the National MS Society offered a brief overview of the Inflation Reduction Act of 2022 and how it relates to the economic impact faced by patients with MS. [WATCH TIME: 5 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]

Paul Doghramji, MD, FAAFP, discusses best practices for referring patients with sleep issues to a sleep specialist.